Akeso
Clinical trials sponsored by Akeso, explained in plain language.
-
New hope in fight against spreading bowel cancer
Disease control Recruiting nowThis study compares two different drug combinations for people newly diagnosed with advanced colorectal cancer that has spread. It tests whether adding a new drug called AK112 to standard chemotherapy works better and is as safe as the current standard treatment of bevacizumab pl…
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Apr 03, 2026 21:13 UTC
-
New hope for aggressive lung cancer: Three-Drug cocktail trial
Disease control Recruiting nowThis study is testing whether adding different investigational drugs to standard chemotherapy works better for adults newly diagnosed with extensive-stage small cell lung cancer. Researchers will compare three treatment groups to see which combination is safest and most effective…
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New drug duo enters human trials for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing the safety and initial effectiveness of combining two experimental drugs, AK119 and AK112, in adults with advanced solid tumors that have stopped responding to standard treatments. The trial will enroll about 87 participants to determine the righ…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New drug combo aims to boost stomach cancer surgery success
Disease control Recruiting nowThis study is testing whether adding a new immunotherapy drug called cadonilimab to standard chemotherapy improves outcomes for people with operable stomach or gastroesophageal cancer. About 760 participants will receive the drug combination or a placebo, both before and after th…
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New hope for tough stomach cancers: trial tests Dual-Attack drug combo
Disease control Recruiting nowThis study is testing a new combination of two immunotherapy drugs, called AK109 and AK104, for people with advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination, given with or without standard chemotherapy, can help control the cancer after…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New hope for pancreatic cancer patients in major drug trial
Disease control Recruiting nowThis study is testing whether adding one or two new drugs (ivonescimab and AK117) to standard chemotherapy works better than chemotherapy alone for people with advanced pancreatic cancer that has spread. About 1,000 participants will be randomly assigned to receive either the new…
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New cancer drug enters human testing for Tough-to-Treat tumors
Disease control Recruiting nowThis early-stage study is testing a new drug called AK138D1 in people with advanced solid cancers that haven't responded to standard treatments. Researchers will give the drug to up to 200 participants to find the safest dose and see if it shows any signs of fighting their cancer…
Phase: PHASE1 • Sponsor: Akeso • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug duo targets tough pancreatic cancer
Disease control Recruiting nowThis study is testing a combination of two investigational drugs, AK130 and AK112, for people with advanced pancreatic cancer that has worsened after up to two prior treatments. The main goals are to see if the drug combination is safe and if it can shrink tumors. The trial will …
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug combo trial offers hope for advanced liver cancer patients
Disease control Recruiting nowThis study is testing a new drug called AK112, given alone or in combination with other treatments, for people with advanced liver cancer. The first part checks safety and finds the right dose, while the second part compares AK112 treatments to current standard care. Researchers …
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Three-Drug attack on tough liver cancer
Disease control Recruiting nowThis study is testing a new combination of three drugs (AK104, AK112, and TT-00420) for people with advanced liver cancer that cannot be treated with surgery. The main goal is to see how well the combination shrinks tumors and controls the disease. It will involve about 100 parti…
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
New Two-Target cancer drug enters first human trials
Disease control Recruiting nowThis is the first study in people to test a new experimental cancer drug called AK146D1. The main goals are to find a safe dose and see how the body processes the drug in up to 200 adults with advanced solid tumors that have progressed after standard treatments. Researchers will …
Phase: PHASE1 • Sponsor: Akeso • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug duo targets tough bile duct cancer after standard treatment fails
Disease control Recruiting nowThis study is testing the safety and effectiveness of a new two-drug combination (AK130 + AK112) for people with advanced bile duct cancer that has worsened after initial treatment. The first part finds the safest dose, and the second part sees how well the drugs work together. I…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
New hope for Tough-to-Treat breast cancer: major trial tests promising drug combo
Disease control Recruiting nowThis large, late-stage study is testing whether adding an investigational drug called AK112 to standard chemotherapy works better than chemotherapy alone for people with advanced triple-negative breast cancer. It aims to see if the combination can better control the cancer and he…
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New Two-Pronged antibody tested to keep aggressive lung cancer at bay
Disease control Recruiting nowThis study is testing whether a new drug called AK112 can help keep small cell lung cancer from coming back in people who have just finished their initial chemo-radiation treatment. About 560 participants will be randomly assigned to receive either the real drug or a placebo (ina…
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope for esophageal cancer: trial tests powerful drug combo to shrink tumors before surgery
Disease control Recruiting nowThis study is testing whether adding a new immunotherapy drug called cadonilimab to standard chemotherapy, given both before and after surgery, works better than chemotherapy alone for patients with a type of esophageal cancer that can be surgically removed. The goal is to see if…
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC